GlassScriptPhysician profile
Kari S Schichor
NPI 1104080951
$2,023.88
in general payments reported to CMS, 2019-2025
25 companies · $352 in 2025
The $352 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $297 · 2020: $216 · 2021: $21.28 · 2022: $225 · 2023: $504 · 2024: $408 · 2025: $352.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,264.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,264.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $349.40 | 2023-2025 | Myfembree |
| Astellas Pharma US INC | $181.32 | 2023-2025 | Veozah, Myrbetriq |
| Hologic Sales and Service, LLC | $169.04 | 2019-2025 | Aptima, Coolseal Generator, Novasure |
| Abbvie INC. | $138.41 | 2019-2023 | Lo Loestrin Fe |
| Therapeuticsmd, INC. | $111.15 | 2019-2022 | |
| Viiv Healthcare Company | $101.26 | 2024 | Apretude |
| Coopersurgical, INC. | $99.69 | 2019-2023 | Paragard T 380a |
| Sage Therapeutics, LLC | $97.07 | 2024-2025 | Zurzuvae |
| Renovia INC | $93.69 | 2020 | |
| Organon LLC | $92.95 | 2024 | |
| Daiichi Sankyo INC. | $86.21 | 2023-2024 | Injectafer |
| Pfizer INC. | $80.95 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $60.26 | 2019-2025 | |
| Myovant Sciences INC. | $50.14 | 2022 | |
| Merck Sharp & Dohme LLC | $45.03 | 2023-2025 | Gardasil 9, Pneumovax 23 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exeltis, USA INC. | $43.07 | 2025 | Slynd |
| Duchesnay USA Incorporated | $38.64 | 2019 | |
| Mylan Pharmaceuticals INC. | $32.93 | 2019-2022 | |
| Millicent US INC | $32.93 | 2020-2023 | Femring, Intrarosa |
| Scynexis, INC. | $28.09 | 2022 | |
| Avion Pharmaceuticals | $25.28 | 2019-2020 | |
| Becton, Dickinson and Company | $21.51 | 2024 | Bd Max System, Bd Max Instrument |
| Mayne Pharma Commercial LLC | $15.41 | 2023 | |
| Ferring Pharmaceuticals INC. | $15.21 | 2020 | |
| Supernus Pharmaceuticals, INC. | $14.24 | 2025 | Qelbree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kari Schichor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.